Cocrystal Pharma (COCP) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Cocrystal Pharma (COCP) over the past year, gaining 23.2% versus a loss of 14.4%. Polyrizon is the larger company by market cap ($21.5 million vs $20.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | PLRZ |
|---|---|---|
| Share price | $1.07 | $8.87 |
| Market cap | $20.52M | $21.54M |
| 1-day change | -0.47% | 0.00% |
| YTD return | +9.18% | +4.48% |
| 1-year return | -14.40% | +23.19% |
| 5-year return | -90.51% | — |
| EPS (TTM) | $-0.76 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $18.20 |
| 52-week low | $0.76 | $2.88 |
| Distance from 52-week high | -47.54% | -51.26% |
| Analyst consensus | none | — |
| Avg. price target upside | +745.07% | — |
| Average volume | 56.00K | 60.55K |
| Shares outstanding | 19.26M | 2.43M |
| Employees | 10 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed COCP by 37.6 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Health Care · Medical/Dental Instruments · 2 employees
COCP vs PLRZ FAQ
Which is bigger, Cocrystal Pharma or Polyrizon?
Polyrizon (PLRZ) is larger, with a market capitalization of $21.54M compared with $20.52M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, COCP or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -14.40% for COCP (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Polyrizon in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cocrystal Pharma and Medical/Dental Instruments for Polyrizon.